Wednesday, 24 Apr 2019

You are here

Update on Pregnancy Management in RA

Two recent reports offer good news to rheumatoid arthritis (RA) women who are planning to become pregnant. 

The first studies, RA women experiencing fertility issues who turn to assisted reproductive technology (ART) shows that live births were significantly lower in women with rheumatoid arthritis receiving ART treatment compared to usual rates in women without rheumatoid arthritis.

A nationwide Danish health registries, studied 1149 embryo transfers in RA women and 198 941 embryo transfers in control women. The adjusted OR (aOR) for a live birth in an RA patient was 0.78 (95% CI 0.65 to 0.92). Corticosteroid prescription prior to embryo transfer increased the OR for live birth (aOR=1.32 (95% CI 0.85 to 2.05)).

These result suggested that the problem was related to an impaired chance of embryo implantation that may be corrected by corticosteroid use before ART, but the latter merits further research.

The second study from OTIS researchers demonstrated in women with RA and JIA who discontinue their  TNF inhibitor (TNFi) before gestational week 20, was associated with with well‐controlled disease.  (Citation source:

From a study of 490 women (397 with RA, 93 with JIA), 25% discontinued a TNFi before gestational week 20, and 41% used a TNFi beyond week 20 and 34.1% did not use a TNFi during pregnancy. At the time of enrollment, disease activity was low to minimal in 72.9% of women.

TNFi discontinuation was not associated with a clinically important worsening of patient reported outcome measures at the third trimester. Although there was a trend towards third trimester improvement with continued TNFi use (beyond week 20), this was not significant in multivariate analysis.

Although data was collected on birth outcomes, it was not included in this report.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Statins in RA Patients Without CVD: Nonsignificant Results

Patients with RA, but without CV disease, who were treated with atorvastatin appeared to experience cardiovascular (CV) benefits similar to what has been observed in other populations, with a risk reduction of approximately one-third, according to a large, but prematurely terminated, trial in the U.K.

Increasing Prevalence and Consequences of Interstitial Lung Disease in RA

Interstitial lung disease (ILD) has been a hot topic in numerous journals recently with reports of increasing incidence and links to disease activity.

RheumNowLive On Demand: MTX Impact in RA - Dr. Michael Weinblatt

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

RheumNowLive On Demand: Pre-Clinical RA - Dr. Michael Holers

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

Artificial Intelligence to Predict Rheumatoid Disease Activity

A recent study in JAMA Network Open shows that artificial intelligence models can use electronic health record data to prognosticate future patient outcomes in rheumatoid arthritis (RA).